Determinants of personal demand for an AIDS vaccine in Uganda: Contingent valuation survey

Bulletin of the World Health Organization

Volumn 82, Issue 9, 2004, Pages 652-660

  Bishai, David ^a   Pariyo, George ^b   Ainsworth, Martha ^c   Hill, Kenneth ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

^c WORLD BANK   (United States)

Author keywords

AIDS vaccines economics; Fees, Pharmaceutical; Health services needs and demand economics; Patient acceptance of health care; Risk taking; Treatment outcome; Uganda

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONTINGENT VALUATION; ECONOMIC ANALYSIS; HEALTH GEOGRAPHY; HOUSEHOLD SURVEY; MARKET CONDITIONS; VACCINATION;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BEHAVIOR; CONDOM; CONTINGENT VALUATION; DEMOGRAPHY; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH BEHAVIOR; HEALTH CARE NEED; HEALTH SERVICE; HEALTH SURVEY; HOUSEHOLD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFECTION RISK; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MONEY; MULTIVARIATE ANALYSIS; PREVALENCE; QUESTIONNAIRE; REVIEW; TREATMENT OUTCOME; UGANDA; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; DATA COLLECTION; FEMALE; HEALTH SERVICES NEEDS AND DEMAND; HEALTH SERVICES RESEARCH; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RISK-TAKING; SEXUAL BEHAVIOR; TREATMENT OUTCOME; UGANDA;

AFRICA; EAST AFRICA; SUB-SAHARAN AFRICA; UGANDA;

EID: 4644307230     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. UNAIDS. Report on the global HIV/AIDS epidemic: July 2002. Geneva: UNAIDS; 2002.
2. Armstrong J. Uganda's AIDS crisis. Washington (DC): World Bank; 1995.
3. Esparza J, Osmanov S, Pattou-Markovic C, Toure C, Chang ML, Nixon S. Past, present and future of HIV vaccine trials in developing countries. Vaccine 2002;20:1897-8.
4. Nature. US launches trial of AIDS vaccine in Uganda. Nature 1999;397:554. [News story.]
5. Hom DL, Johnson JL, Mugyenyi P, Byaruhanga R, Kityo C, Louglin A, et al. HIV-1 risk and vaccine acceptability in the Ugandan military. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1997;15:375-80.
6. Mugerwa RD, Kaleebu P, Mugyenyi P, Katongole-Mbidde E, Hom DL, Byaruhanga R, et al. First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ 2002;324:226-9.
7. Jackson DJ, Martin HL, Jr, Bwayo JJ, Nyange PM, Rakwar JP, Kashonga F, et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS 1995;9:1279-83.
8. Stover J, Garnett G, Seitz S, Forsythe S. The epidemiological impact of an HIV/AIDS vaccine in developing countries. Washington (DC): World Bank; 2002.
9. Mitchell R, Carson R. Using surveys to value public goods: the contingent valuation method. Washington (DC): Resources for the Future; 1989.
10. Whittington D. Administering contingent valuation surveys in developing countries. World Development 1998;26:21-30.
11. Smith RD. Construction of the contingent valuation market in health care: a critical assessment. Health Economics 2003;12:609-28.
12. Suraratdecha C, Ainsworth M, Tangcharoensathien V, Whittington D. The private demand for an AIDS vaccine in Thailand, Health Policy. In press 2004.
13. Filmer D, Pritchett L. Estimating wealth effects without expenditure data - or tears: an application to educational enrollments in states of India. Demography 2001;38:115-32.
14. McGrath JW, George K, Svilar G, Ihler E, Mafigiri D, Kabugo M, et al. Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. Journal of Acquired Immune Deficiency Syndromes 2001;27:381-8.
15. Gray RH, Li X, Wawer MJ, Gange SJ, Serwadda D, Sewankambo NK, et al. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission: Rakai, Uganda. AIDS 2003;17:1941-51.